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A B S T R A C T
Melatonin is not only synthesized by the pineal gland but by several ocular structures. This natural indoleamine
is of great importance for regulating several eye processes, among which pressure homeostasis is included.
Glaucoma, the most prevalent eye disease, also known as the silent thief of vision, is a multifactorial pathology
that is associated to age and, often, to intraocular hypertension (IOP). Indeed IOP is the only modifiable risk
factor and as such medications are available to control it; however, novel medications are sought to minimize
undesirable side effects. Melatonin and analogues decrease IOP in both normotensive and hypertensive eyes.
Melatonin activates its cognate membrane receptors, MT1 and MT2, which are present in numerous ocular tis-
sues, including the aqueous-humor-producing ciliary processes. Melatonin receptors belong to the superfamily of
G-protein-coupled receptors and their activation would lead to different signalling pathways depending on the
tissue. This review describes the molecular mechanisms underlying differential functionalities that are attributed
to melatonin receptors. Accordingly, the current work highlights the important role of melatonin and its ana-
logues in the healthy and in the glaucomatous eyes, with special attention to the control of intraocular pressure.
1. Melatonin discovery and synthesis
1.1. Introduction
In the search for substances to treat vitiligo, the dermatologist
Aaron Lerner discovered in late 50s a molecule produced by the bovine
pineal gland that was able to lighten amphibian melanocytes by causing
the aggregation of melanin near the nucleus of the cells (Lerner and
Case, 1959). Lerner and colleagues focused their research on the active
substance from pineal gland which was first named as melatonin and
further identified as N-acetyl-5-methoxytryptamine, an indoleamine
(Lerner et al., 1960). Melatonin is composed of the prefix “mela”, which
refers to melanin, and the suffix “tonin” because serotonin is its pre-
cursor (Reiter et al., 2014a). Although the main aim of Lerner's and
colleagues research was the therapy of skin ailments, the discovery of
melatonin paved the way to demonstrate the involvement of the in-
doleamine in regulation of a wide variety of physiological processes.
Lerner and his team were the first to notice that melatonin was able to
induce sleep (Lerner and Nordlund, 1978), hence attracting the atten-
tion of scientists in the field of circadian rhythms.
Melatonin metabolism in the pineal gland starts by hydroxylation of
tryptophan uptaken by pinealocytes. Hydroxylated tryptophan becomes
decarboxylated by the L-aromatic amino acid decarboxylase to form,
serotonin, the biogenic amine (Axelrod, 1974). The first rate-limiting
enzyme in most reported studies of melatonin synthesis, named ar-
ylalkymine N-acetyltransferase (AANAT), uses a small percentage of the
produced serotonin (around 5–25%) and catalyzes the transfer of the
acetyl group from acetyl-CoA to serotonin. N-acetyl-serotonin (NAS) is
finally converted to melatonin, by hydroxyindole-O-methyltransferase
(HIOMT), a cytosolic protein which constitutes 2–4% of total soluble
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proteins in the pineal gland. The enzyme catalyzes the O-methylation of
NAS using S-adenosyl methionine as a single carbon donor and its in-
volvement in melatonin synthesis was observed in the rat pineal gland
(Liu and Borjigin, 2005).
The process of melatonin synthesis is driven by circadian rhythms,
reaching a concentration peak at night (Pevet, 2002, 2014; Tosini and
Fukuhara, 2003; Zawilska et al., 2002). In extrapineal structures, mel-
atonin synthesis does not follow circadian rhythms; in addition it has
been reported that mitochondria may produce the compound (Suofu
et al., 2017). The increase of melatonin synthesis at night is stimulated
by signals originated at neurons of the suprachiasmatic nucleus (SCN).
Via the eyes, these neurons receive information about the time of the
day and send inputs through the paraventricular nucleus (PVN) to the
spinal cord and the superior cervical ganglia (SCG) of the sympathetic
nervous system. Such adrenergic fibers are located adjacent to pine-
alocytes (Moore and Klein, 1974), in which norepinephrine receptors
become activated. In fact, norepinephrine may bind to α- and β-adre-
nergic receptors present in the cell surface of pinealocytes and each
receptor mediates the regulation of melatonin synthesizing-enzyme
expression. β-adrenoceptor activation stimulates a heterotrimeric Gs
protein that activates adenylyl cyclase to produce cAMP from ATP.
cAMP, the main second messenger in mammalian cells, activates the
protein kinase A pathway that in turns enhances the expression of
AANAT and/or boosts its catalytic activity (Klein et al., 1992, 1997;
Minneman and Iversen, 1976). In contrast, the stimulation of α-adre-
noceptors activates a Gq protein that is linked to the phospholipase C
(PLC)-phosphatidylinositol-protein kinase C (PKC) cascade (Fig. 1). In
such pathway the main second messenger is calcium ion, whose role in
the expression of melatonin-metabolizing effects is not known. How-
ever, PKC may act on adenylate cyclase to enhance cAMP levels,
AANAT activity and melatonin synthesis (Ho et al., 1988). Accordingly,
pineal AANAT activity may be regulated by neurotransmitters that act
via cAMP-related mechanisms (Hardeland, 2008).
Melatonin levels rise at night due to release from the pineal gland to
the cerebrospinal fluid as well as to the blood stream (Reiter et al.,
2014b; Tan et al., 2016) (Fig. 1). Although the first hypothesis pointed
to melatonin being uniquely synthesized by the pineal gland, mela-
tonin-synthesizing enzymes were detected in cells other than those in
the pineal gland (Acuña-Castroviejo et al., 2014). Of particular interest
for this review is the presence of melatonin in the eye, the underlying
mechanisms and its specific function(s) in the physiology of the eye.
1.2. Sources of melatonin in the eye
After its identification in the pineal gland, synthesis of melatonin
was detected in different regions of the brain, among others in the
hypothalamus, the habenula (Axelrod et al., 1961) and the cerebellum
(Bubenik et al., 1974). The retina was one of the first structures where
the melatonin synthesis was identified (Huang et al., 2013; Nagle et al.,
1973). The finding was confirmed by detecting melatonin-synthesizing
enzymes even after pinealectomy. Interestingly, Bubenik and colla-
borators showed that N-acetylindolealkylamines in the retina do not
come from axons coming from neurons in the optic nerve (Bubenik
et al., 1974). The relevance of these results was questioned due to the
lack of HIOMT in the human retina (Bernard et al., 1995). However,
melatonin is indeed produced in different cell types of the human eye.
As an example Zmijewski et al. (2009) reported that the indolamine was
produced by human retinal pigment epithelial ARPE-19 cells; more
examples are provided below (Zmijewski et al., 2009).
An interesting approach to the in vitro study of melatonin synthesis
is to provide the melatonin precursor, tryptophan, by continuous per-
fusion. One experiment done in late 90s showed that addition of tryp-
tophan to the harderian gland, a juxtaorbital gland existing in some
vertebrates, increases melatonin release up to 2.5-fold higher than
melatonin released from untreated samples (Djeridane et al., 1998).
Experiments in the same laboratory aiming at investigating melatonin
production showed that unlike the pineal gland, melatonin levels in the
harderian gland do not change according to the time of the day
(Djeridane and Touitou, 2001).
Another ocular structure where melatonin may be synthesized is in
the crystalline lens. Melatonin and its precursors were detected in
rabbit lenses, together with the activity of both synthesizing enzymes,
AANAT and HIOMT. Moreover, melatonin and AANAT followed a cir-
cadian rhythm similar to that in the pineal gland, being significantly
higher during the night in comparison to daylight (Abe et al., 1999).
Melatonin has been also found in the iris and ciliary body. This was
a likely hypothesis due to melatonin regulation of IOP (see below), due
to the existence of diurnal changes in the intraocular pressure (IOP),
and due to ciliary epithelium sharing the same embryonic origin than
the pineal gland and the retina. In fact, Martin and collaborators found
Fig. 1. Scheme of melatonin synthesis in the pineal
gland (left) and of daily rhythmicity of indole levels
(right). Serotonin levels are high during the day and
decrease at night (grey) because of an increase in
AANAT expression and activity due to signals of
darkness coming from the eye through the
Suprachiasmatic nucleus (SCN). AANAT transfers an
acetyl group from acetyl CoA to 5-HT. The increase
in AANAT activity results in an increase in the in-
tracellular concentration of N-acetyl serotonin,
which is converted to melatonin by hydroxyindole-
Omethyltransferase (modified from Klein, 1974).
AANAT, arylalkylamine N-acetyltransferase; AC,
adenylyl cyclase; HIOMT, hydroxyindole-O-me-
thyltransferase; cAMP, cyclic adenosine monopho-
sphate; CREB, cAMP response element-binding
protein; NAS, N-acetyl 5-methoxytryptamine; NE,
norepinephrine; PKA, protein kinase A.
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serotonin, 6-hydroxymelatonin, and melatonin in the aqueous humor.
Moreover, tryptophan, 5-hydroxytryptophan, serotonin, and 5-hydro-
xyindoeacetic were detected in ciliary bodies from quickly enucleated
human eyes (Martin et al., 1992; Osborne, 1994). It was noteworthy to
find that HIOMT activity was 50 times higher than that of AANAT, thus
indicating that AANAT is the rate limiting enzyme in melatonin
synthesis, an observation found also in the pineal gland (Klein, 2007;
Martin et al., 1992).
1.3. Melatonin receptors and signalling pathways
Both melatonin production in numerous ocular structures and the
higher concentration in the aqueous humor than in blood are evidence
of relevant roles of the indoleamine in eye physiology and function.
First of all, the action of melatonin seems mainly mediated by cell
surface receptors, two of which MT1 and MT2, have been cloned and
characterized (Morgan et al., 1989; Reppert, 1997; Reiter, 1991;
Reppert et al., 1995; Reppert et al., 1994; Rivara et al., 2005). They
have a relatively high degree of homology and are members of the
superfamily of G-protein-coupled receptors (GPCRs). Occurrence of a
putative MT3 receptor was reported on the basis of pharmacological
evidence (Pintor et al., 2001). This activity was later attributed to
quinone reductase 2 (QR2) (Mailliet et al., 2004), whose enzyme ac-
tivity seems regulated by melatonin and by other endogenous (e.g. N-
acetylserotonin) and exogenous compounds (e.g. resveratrol). These
compounds act as negative allosteric modulators thus inhibiting the
enzyme, which plays a role in reduction-oxidation (REDOX) mechan-
isms occurring between quinones, semiquinones, and hydroquinones. It
is not clear whether QR2 has a relevant role in melatonin physiology
although the data on the 5-MCA-NAT-QR2 interaction suggest that
dopamine may indirectly mediate actions resulting from melatonin
regulation of QR2 activity; in fact, melatonin inhibits dopamine release
from amacrine cells (Lavoie et al., 2013; Sampaio Lde et al., 2014;
Wiechmann and Sherry, 2013).
Apart from MT1 and MT2, the GPR50 orphan receptor shares 45%
amino acid homology with melatonin receptors (Dufourny et al., 2008);
nevertheless, melatonin does not bind to this receptor and the en-
dogenous agonist has not been unambiguously identified (Reppert
et al., 1996). A functional interaction between melatonin receptors and
GPR50 has been reported. The orphan GPCR may directly interact with
MT1 to inhibit the actions mediated by MT1 receptor (Levoye et al.,
2006); the effect seems to be mediated by the C-terminal domain of
GPR50. Deletion of the C-terminal tail of GPR50 led to abolishment of
the inhibitory effect of GPR50 on MT1 but without affecting hetero-
dimerization (Li et al., 2013). The physiological meaning of such
findings requires more experimental effort.
When individually expressed, MT1 and MT2 receptors couple to a
heterotrimeric Gi protein. There are several members of G proteins,
which are classified in four main categories (Zachariou et al., 2012). On
the one hand, the Gs family stimulates adenylyl cyclase and leads to the
increase of cAMP levels and subsequent protein kinase A (PKA) acti-
vation. On the other hand, members of the Gi family (which includes
Gz, Go and Ggust) inhibit adenylyl cyclase to decrease cAMP levels and
deactivate PKA but also regulate some K+, and voltage-gated Ca2+
channels. Gq proteins mediate phosphoinositide (PI) turnover and in-
crease phospholipase C activity and cytosolic [Ca2+]. Finally, members
of the G12 family regulate the activity of Rho-guanine nucleotide ex-
change factors.
Cognate proteins coupled to both melatonin receptors are of the Gi
class (Fig. 2). Indeed, the activation of MT1 or MT2 receptors associates
to reduction of forskolin-induced [cAMP] levels (Vanecek, 1998). By
this canonical mechanism the PKA pathway is inactivated (von Gall
et al., 2000). Depending on the experimental model, melatonin re-
ceptors may couple to other G proteins (Fig. 2) (Tslm et al., 1996). It is
under question whether Gs activation may occur via MT1 in human
prostate epithelial cells in which receptor-mediated antiproliferative
action of melatonin seemingly involves dual activation of Gs and Gq
proteins (Shiu et al., 2010). In addition, MT1 and MT2 receptors in
transfected COS-7 cells may couple to the G16 protein (Lai et al., 2002;
Mody et al., 2000).
Involvement of calcium ion as second messenger has been suggested
for a variety of GPCRs that are coupled to Gs or Gi. However the un-
derlying mechanism of intracellular calcium mobilization is con-
troversial. A direct pathway would be mediated by Gq-coupled mela-
tonin receptors. Activation of Gq has been demonstrated for the MT1
receptor-expressing gastrointestinal smooth muscle cells, with con-
comitant PLC activation and increases in cytosolic Ca2+ levels and PI
hydrolysis (Ahmed et al., 2013). Activation of the MT1 receptor ex-
pressed in the HEK-293T cell line engages the phospholipase C-α (PLC-
α) pathway (Brydon et al., 1999), while activation of the MT2 receptor
has been associated to changes in the activity of guanylate cyclase (Petit
et al., 1998). In summary, the versatility of melatonin receptors in
terms of signalling pathways may be partially related to a shift in the
coupling to G proteins. In vitro and in cell lines, melatonin receptors
have the capacity to couple to multiple G proteins but identifying the
interactions that are relevant from a physiological point of view will
require further experimental effort and insights into melatonin re-
ceptor-G protein structures. The most plausible hypothesis is that Gi is
the cognate protein of melatonin receptors (as IUPHAR recognizes) and
that coupling to other G proteins may occur “artificially” in hetero-
logous expression systems or be physiological when melatonin re-
ceptors interact with other receptors/proteins (see below for examples).
1.4. Wide expression of melatonin receptors in the eye
Melatonin receptors are not only expressed in the CNS (for instance
in the suprachiasmatic nucleus, pars tuberalis and visual areas) but in
several ocular components. Accordingly, the role of melatonin receptors
in eye physiology is of paramount importance. In addition, they med-
iate the night-day circadian rhythms in which eyes are at the centre
stage (Iuvone et al., 2005; von Gall et al., 2002; Wiechmann and
Summers, 2008; Zawilska, 1992).
In vertebrates, the neural retina consists of various neuronal cell
Fig. 2. Signalling events upon melatonin MT1 and MT2 receptor activation. Gi is
the cognate protein to which receptors couple; accordingly, their activation
reduces adenylyl cyclase (AC) activity, cAMP levels, cAMP-dependent protein
kinase (PKA) activity and cAMP response-element-binding (CREB) is mostly in
nonphosphorylated form (right). In circumstances in which there is Gq cou-
pling, an alternative route due to overexpression in heterologous cells or in-
teraction with other receptor/proteins happens. Gq engagement leads to
phospholipase C (PLC) activation and cleavage of phosphatidylinositol dipho-
sphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG); these
compounds in turn lead to increase cytosolic [Ca2+] and protein kinase C (PKC)
activity (left).
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types, among other photoreceptor, horizontal, bipolar, amacrine, in-
terplexiform and ganglion cells. Melatonin participates in the circadian
switching from cone to rod-driven functions (Cahill and Besharse,
1995). Hence it is anticipated that activation of melatonin receptors
would result in an end-point in cone function to enhance rod func-
tionality (Wiechmann and Sherry, 2013). Apart from their presence in
the photoreceptor cells, melatonin receptors are expressed in the outer
and inner parts of the retina (Wiechmann, 2003; Wiechmann and
Sherry, 2012). In human, monkeys and rats, MT1 receptor is present in
the horizontal cells in the inner and outer plexiform layer and in all
amacrine cells (Fujieda et al., 1999, 2000; Scher et al., 2002), where it
probably regulates the release of neurotransmitters such as acetylcho-
line (Fujieda et al., 1999). MT1 but not MT2 receptors are located in
dopaminergic and GABAergic neurons where they regulate the release
of GABA and dopamine from amacrine cells (Dubocovich, 1983). Mel-
atonin also modulates, via melatonin receptors, dopamine release from
retinal neurons (Dubocovich, 1983) and retinomotor movements, and
mediates circadian outer segment disc shedding (Pierce and Besharse,
1985; White and Fisher, 1989).
Other ocular structures where the melatonin MT1 receptor was
found are the choroid and the sclera. Although little is known about
relevance for humans; evidence shows that MT1 receptors are expressed
in chick choroid, which in turn present diurnal fluctuations in thick-
ness, perhaps due to constriction of blood vessels (Nickla et al., 1998;
Rada and Wiechmann, 2006). Furthermore, evidence of the presence of
melatonin receptors in chick sclera suggested the participation of
melatonin in ocular elongation and growth (Nickla et al., 1999;
Wiechmann et al., 2004).
Xenopus leavis is a frog whose eye exerts a pineal-like function as it
produces the melatonin that is released into the blood. The MT1 re-
ceptor is present in the outer and inner fibrous layer of the sclera of
Xenopus laevis, and to a lesser extent in the cartilaginous layer
(Wiechmann and Rada, 2003). In this frog, MT2 receptor is present in
the distal portion of the outer fibrous layer, but not in the inner fibrous
layer. Existing data suggest that the MT2 receptor is the main melatonin
receptor in the lens fiber cells of Xenopus laevis (Wiechmann et al.,
2004). It is suggested that MT2 receptors are the target of melatonin
synthesized by the human lens in which AANAT activity is modulated
by light/dark cycles. Indeed the expression of the enzyme is markedly
enhanced at night (Fig. 3) (Abe et al., 1999; Alkozi et al., 2017d). It
should be noted that melatonin protects against cataracts produced by
ultraviolet light or by oxidative stressors such as buthionine sulfoximine
(Abe et al., 1994; Bardak, 2000).
The iris regulates the amount of light entering the eye, while the
ciliary body is mainly responsible for aqueous humor production.
Melatonin receptors are expressed in these structures (Osborne and
Chidlow, 1994) (Dortch-Carnes and Tosini, 2013) and in the cornea, the
most superficial structure of the eye facing all of the stress coming from
the environment (DelMonte and Kim, 2011). In mammals, melatonin
receptor MT2 was detected in corneal epithelium and endothelium and
its activation affects circadian rhythm entrainment (Baba et al., 2015).
Additionally, MT2 receptors play a role in corneal wound healing
(Crooke et al., 2015).
The wide distribution of melatonin receptors in the eye and the
differential expression of MT1 and MT2 receptors in the ocular struc-
tures suggest multiple functions that will require more experimental
effort for complete elucidation (Wiechmann et al., 2004).
2. Aqueous humor and intraocular pressure
Early results from measuring IOP in a large healthy population
(10,000 individuals) showed a Gaussian distribution with a mean of
15–16 ± 2 mmHg (Leydhecker et al., 1958). Ulterior studies confirmed
those values and the reference values were established in the
9–21 mmHg range (Colton and Ederer, 1980). Abnormal values are
those found in 97.5 percentile and, in practice, eye hypertension is
considered when IOP > 21 mm Hg. Elevated eye tension is not con-
sidered a pathological process per se, although it constitutes a risk
factor for certain ocular pathologies such as glaucoma (Casson et al.,
2012a).
IOP constitutes the physical substrate needed to keep intraocular
structures in place. In fact, the intraocular pressure is a result of a hy-
drostatic balance in which the aqueous humor, the lens, the vitreous,
the uvea and the corneoscleral wall (the container) participate (Aptel
et al., 2016). Its value is kept within a narrow range thanks to a dy-
namic equilibrium between the production and drainage of the aqueous
humor. Although episcleral vein pressure and circadian rhythms also
contribute to IOP, the main issue in ocular hypertension is the
Fig. 3. Light-induced effect on AANAT ex-
pression in human lens epithelial cells.
Panels A–B: Analysis by Western-blot of
AANAT expression after 8 h of light or
darkness. Values in B are the mean ± SD
(n = 6; **p < 0.01). Panel C:
Immunohistochemical study performed in
human lens epithelial cells showing the
changes in AANAT expression (nuclei ap-
pear in red). A negative control was per-
formed using human chondrocytes. Taken
from (Alkozi et al., 2017d) with permission
(Elsevier).
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alteration in the balance between production and drainage of the
aqueous humor (Brubaker, 1991).
The aqueous humor is a transparent fluid, somewhat similar to
blood plasma, that bathes the anterior and the posterior ocular cham-
bers (Adler, 1933; Civan and Macknight, 2004; Davson et al., 1936). It
is secreted into the posterior chamber by cells in the ciliary processes, it
circulates through the pupil and passes into the anterior chamber from
where it is drained by two main routes, the conventional pathway
(trabecular meshwork-Schlemm's canal-aqueous veins), and the non-
conventional uveoscleral drainage pathway (Bill, 1966). The circulation
of the aqueous humor serves to a myriad of functions such as providing
oxygen and nutrients to the cornea, lens, and trabecular meshwork, but
also to the pressure needed for avoiding eye collapse (Krupin et al.,
1986).
The aqueous humor dynamics changes according to circadian
rhythms. For instance, the rate of aqueous humor formation in humans
drops from 2.6 μl/min during daytime to 1.1 μl/min at night (McCannel
et al., 1992); therefore IOP is lower at night. These circadian changes in
IOP values are due to the communication between the ciliary body and
the suprachiasmatic nucleus and to several regulatory signals, for in-
stance those exerted by norepinephrine, cAMP, adenosine, dopamine,
and melatonin. However, circadian fluctuations in a healthy eye are
very limited, i.e. they lie within a 3–5 mmHg range (Coca-Prados and
Escribano, 2007; Osborne and Chidlow, 1994).
The nervous control of IOP is exerted by both sympathetic (adre-
nergic) and parasympathetic (cholinergic) systems (Bergmanson,
1982). The origin of adrenergic nerves lies in the fibers coming from the
ipsilateral superior cervical ganglion. Each ciliary process contains
adrenergic nerves, although the density of such innervation varies
across species (Ehinger, 1966; Ehinger et al., 1969). The para-
sympathetic cholinergic nerves originate in post-ganglionic fibers of the
pterygopalatine ganglia, which originate from preganglionic neurons in
the superior salivary nucleus located in the dorsal pons (pontine teg-
mentum) in the brainstem. These post-ganglionic fibers innervate the
structures involved in intraocular pressure regulation, e.g. the ciliary
epithelium and trabecular meshwork (Ten Tusscher et al., 1990).
IOP is not only controlled by aqueous production routes but by re-
ceptors present in aqueous humor outflow drainage pathways (Nomura
and Smelser, 1974; Selbach et al., 2000). The link between IOP and
both adrenergic and cholinergic receptors was established by the use of
pharmacological tools; in this sense, phenylephrine, the endogenous
adrenoceptor agonist reduces the junctions between pigmented and
non-pigmented ciliary processes in cows and rabbits. Similar results
were observed using carbachol, a cholinergic receptor agonist. A re-
duction in the interfaces between both pigmented and non-pigmented
epithelium layers, together with inhibition of adenylyl cyclase, are re-
sponsible of reducing aqueous humor production (Shi et al., 1996).
Cholinergic agonists such as pilocarpine are used to reduce resistance of
aqueous outflow through the trabecular meshwork (Diestelhorst et al.,
2002). It was reported that agonists of α1-receptors increase IOP,
whereas agonists and antagonists of α2-receptors inhibited aqueous
humor outflow less than production, thus leading to IOP decreases;
authors concluded that “The conventional theory of receptor antagonism
does not seem to function at α2-receptor sites” (Chiou, 1983). Probably the
results of α2-adrenoreceptor agonists are dual as they also affect tra-
becular meshwork resistance (Hodapp et al., 1981). Activation of ß-
adrenoceptors in the healthy human eye, for instance using salbutamol,
consistently leads to increase of uveoscleral outflow and decrease in
IOP (Coakes and Siah, 1984). These findings have been instrumental for
the design of medications prescribed today to reduce IOP.
2.1. Glaucoma: from pathology to therapy
According to the US National Eye Institute (NIH-NEI), glaucoma is
“a group of diseases that damage the eye's optic nerve and can result in vision
loss and blindness”. Often, glaucoma is a disease resulting from increased
scleral rigidity occurring upon aging. Neurodegeneration affects retinal
ganglion cell death and courses with reduction of axons in the optic
nerve. Aging is a risk but, interestingly, NIH-NEI indicates that the risk
is higher in “African Americans over age 40 and everyone over age 60,
especially Mexican Americans” (Facts About Glaucoma, 2015) (https://
nei.nih.gov/health/glaucoma/glaucoma_facts). Genetic factors also
contribute and the risk increases if progenitors or grandparents have
suffered from glaucoma (Casson et al., 2012b; Quigley, 2011). Glau-
coma is considered the second leading cause of blindness and the first if
only irreversible blindness is considered. A study done in 2006 has
estimated about 61 million individuals suffering from glaucoma. It is
estimated that, by 2020, glaucoma will affect 80 million persons
(Quigley and Broman, 2006).
Two different glaucoma types must be highlighted: the angle-clo-
sure disease is due to a mechanical narrowing in the irido-corneal
outflow structures, whereas the open-angle glaucoma occurs without
marked changes in the shape of these structures (Casson et al., 2012b;
Foster et al., 2002). Nearly three quarters of all glaucoma cases occurs
in individuals with open irido-corneal angle, i.e. open-angle glaucoma
is the most common form of the disease in virtually all countries. The
vast majority is idiopathic and, therefore, is referred to as primary
open-angle glaucoma (POAG) (Quigley and Broman, 2006). Up to 40%
disappearance of nerve fibers of the retina can happen without any
gross manifestation of functional loss in open-angle glaucoma (Foster
and Johnson, 2001); see (Pan and Varma, 2011) for review and his-
torical perspective. The disease may affect one or both eyes and the first
clinical symptom consists of loss of peripheral vision. Open angle
glaucoma may occur without increase in IOP and, conversely, not all
individuals with eye hypertension develop glaucoma. When open-angle
glaucoma correlates with increased IOP, the measurement of this
parameter is instrumental to control for the efficacy of pharmacological
treatments (Liu et al., 2018).
Numerous factors impact on the initiation of neurodegeneration:
among other, ageing, intraocular pressure, and marked myopia
(Quigley, 2011). This condition is named the silent thief of sight since it
is asymptomatic and, if untreated, leads to vision loss. Glaucoma does
not necessarily mean that IOP is above reference values. Actually, open-
angle glaucoma defining criteria do not include elevated IOP. However,
prevention measures include IOP measurement as it is easy to measure
and it is indeed an associated risk factor (Leske, 2007; Quigley, 2011).
Furthermore, lowering IOP is considered the first therapeutic approach,
even in patients presenting IOP readings within reference values
(Danias and Podos, 1999; Leske et al., 1999).
It is proven that IOP lowering prevents progression of the disease,
i.e. retards visual field loss and protects optic nerve (Boland et al.,
2013). Pharmacological lowering of IOP using eye drops, or laser in-
tervention in the trabecular meshwork, are preferred than the more
aggressive surgical procedures (Ederer et al., 2004). A common and
effective surgical approach is trabeculectomy surgery, which consists of
making a small incision in the sclera to introduce a bleb allowing
control on aqueous humor drainage (Quigley, 2011). To reduce the
ocular hypertension with eye drop galenic formulations, para-
sympathomimetic drugs, adrenergic receptor antagonists, carbonic an-
hydrase inhibitors or prostaglandins have been approved for human
therapy (Hommer, 2010; Lee, 2005). The range of IOP decrease is
20–40%, which is usually efficacious in preventing vision loss with the
exception of patients presenting fast progression (Quigley, 2011).
Despite the numerous pharmacological options to lower IOP, they
are not absent of undesirable adverse reactions. β blockers may worsen
dry eye symptoms and conjunctival hyperemia but, more importantly
they may provoke bradycardia, arrhythmia and bronchospasms (Hoyng
and van Beek, 2000). Prostaglandins use may end up in headache,
upper respiratory tract alterations, iris pigmentation, uveitis and/or
reactivation of herpetic keratitis (Marquis and Whitson, 2005). Car-
bonic anhydrase inhibitors could produce ocular stinging, burning,
itching and, in some cases, they may alter the corneal endothelium in
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an irreversible fashion (Konowal et al., 1999). There is still a demand
for new tools to combat glaucoma with less side effects (Pintor et al.,
2003). In the meantime adverse events are managed by combining
different drugs and/or combining periods of treatment with one drug
with periods of treatment with a drug of another class (Polo et al., 2001;
Sakai et al., 2005).
2.2. Mechanisms to reduce IOP
IOP decrease may be achieved by either regulating the aqueous
humor formation or by facilitating the flow through the trabecular
meshwork. Agents used to reduce aqueous inflow are β-adrenergic
antagonists, carbonic anhydrase inhibitors, and α2-adrenergic agonists.
As for β-adrenergic antagonists, a topical instillation of this agent leads
to decreases in cAMP in ciliary epithelial cells and, accordingly, re-
duction in the aqueous humor production (Coakes and Brubaker, 1978).
Inhibitors of isozymes of carbonic expressed in ciliary processes in-
crease bicarbonate ion and result in decreased aqueous humor secretion
(Mincione et al., 2007). The mechanism proposed for α2-adrenergic
agonists involves a Gi-mediated vascular constriction; a reduction in
cAMP would reduce phosphorylation of myosin light chain kinase by
PKA. Prevention of vascular relaxation would decrease blood flow and
aqueous humor formation (Reitsamer et al., 2006; Remaury et al.,
1993). Mechanisms underlying the efficacy of prostaglandin analogues
and prostamides are not known although these molecules act on the
trabecular meshwork where they alter permeability and allow
uveoscleral outflow to consequently decrease IOP (Crichton et al.,
2013; Gaton et al., 2001).
2.3. Melatonin: a relevant player in IOP regulation
In several species including humans, the IOP follows a circadian
rhythm just inversely as that of melatonin. IOP is higher during the day,
when [melatonin] (in the CNS, the blood and the eye) displays lower
values. This relationship occurring in daytime also applies at night time
(Wurtman et al., 1963). Therefore, it was temping to speculate that
melatonin could be behind changes in IOP; this hypothesis was correct
as demonstrated in different laboratories (al-Qassab et al., 1988;
Belforte et al., 2010; Chiou and McLaughlin, 1984; Pintor et al., 2001).
Remarkably, melatonin levels may be significantly altered in eye
pathologies, for instance, in glaucoma (Ma et al., 2018). In this sense,
studies analyzing melatonin levels in the aqueous humor of patients
having cataract surgery showed that normotensive cases (IOP <
21 mmHg) had lower melatonin levels than individuals having elevated
IOP (IOP > 21 mmHg) (Fig. 4) (Alkozi et al., 2017a). This finding
correlates with another in which [melatonin], measured in blood, was
higher in patients with glaucoma (Ma et al., 2018). Furthermore, when
aqueous humor of a glaucomatous model (DBA/2J) is compared with
that of control mice (C57BL/6J), it is shown that melatonin levels are
similar in control and DBA/2J before the establishment of pathology.
However, aged DBA/2J mice, which overtly present eye hypertension,
display increased levels of the indoleamine. The model also shows a
linear correlation between IOP and the melatonin concentration (Fig. 5)
(Alkozi et al., 2017a). Increase in concentration is also evident in the
aqueous humor of patients suffering from proliferative diabetic re-
tinopathy, albeit in this case the levels in blood are not altered. Taken
together, the results indicate that the increase of melatonin in the eye of
glaucoma patients is mainly produced by ocular structures and it is not
due to melatonin coming from the pineal gland (Aydin and Sahin,
2016).
The reported results cannot explain why melatonin is increased in
glaucoma coursing with eye hypertension when the compound itself is
able to lower IOP (Ismail and Mowafi, 2009). Interestingly, melatonin
and its analogues such as agomelatine or methoxycarbonylamino-N-
acetyltryptamine (5-MCA-NAT), when topically applied to normoten-
sive eyes of control animals or to hypertensive eyes of aged DBA/2J
mice, are able to afford a significant decrease in IOP (Crooke et al.,
2013; Martinez-Aguila et al., 2013, 2016).
Non-pigmented ciliary body epithelial cells are likely responsible for
the changes of melatonin levels due to increased IOP. Activation in
these cells of a channel sensitive to mechanical pressure, the vanilloid
transient receptor potential channel 4, TRPV4, results in increased
melatonin production (Alkozi and Pintor, 2015). TRPV4 was first
identified as an osmosensor, i.e. a stretch-gated channel. At present, it is
acknowledged that it is not a classical osmosensor but a regulator of
numerous events in both physiological and pathological conditions
(Liedtke, 2007). The polyvalent mode of action of TRPV4 is essential for
osmoregulation and Ca2+ homeostasis in the mammalian ciliary body
(Jo et al., 2016). The TRPV4 is expressed in secretory and absorptive
epithelia, regulating Ca2+ signalling and cytoskeletal remodeling, and
responding to volume changes, shear flow and mechanical stress
(Harteneck and Reiter, 2007; Krizaj et al., 2014; Mamenko et al., 2015;
Sokabe et al., 2010).
GSK1016790A, a selective TRPV4 channel agonist, leads to a dose-
dependent increase in melatonin levels, that is abolished by selective
TRPV4 antagonists (Alkozi and Pintor, 2015). Due to the correlation
between melatonin levels and IOP in glaucoma patients, it is suggested
that the channel acts in the ciliary body as a pressure sensor. The me-
chanism of melatonin synthesis induction following TRPV4 activation
consists of an increase in AANAT activity. Upon TRPV4 activation,
AANAT expression is enhanced and the levels of both melatonin and
NAS in the extracellular medium of human ciliary body cells raise, i.e.
these cells are able to produce the indolamine (Fig. 6) (Alkozi et al.,
2017c). A small interference siRNA approach confirmed that all those
effects are mediated by TRPV4 (Alkozi et al., 2017b). In summary, the
activation of the channel results in a significant increase in the activity
of the melatonin-synthesizing enzyme (AANAT).
One relevant aspect of AANAT concerns its degradation, which is
regulated by phosphorylation/dephosphorylation. The human AANAT
amino acid sequence contains a conserved casein kinase and a putative
protein kinase C phosphorylation sites (Coon et al., 1996). Second
messengers and signal transduction events affect the degree of enzyme
phosphorylation and it is thought that decreases in [cAMP] leads to a
decrease in AANAT activity (Klein, 1978; Klein et al., 1992). It seems,
however, that cAMP may also regulate proteasome action on AANAT
(Gastel et al., 1998). AANAT may bind to regulatory 14-3-3 proteins
that are expressed as dimers. Complex rearrangements occur at night by
cAMP-dependent phosphorylation of the enzyme resulting in activation
and protection against proteolysis (Muslin et al., 1996). In the human
pineal gland, AANAT bind and stabilize 14-3-3 proteins. More precisely,
two pAANAT molecules form a moderately stable complex with two 14-
Fig. 4. Panel A: HPLC was used to isolate and quantify melatonin from human
aqueous humor samples of patients with IOP above 21 mmHg and below
21 mmHg. The bar plot shows the concentration of melatonin in the two po-
pulations of patients (*p < 0.039). Taken from (Alkozi et al., 2017a) with
permission (Wiley).
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3-3 proteins, which undergo dissociation/re-association cycles. When
dissociated pAANAT is dephosphorylated, it does not re-associate while
it is degraded. This mechanism plays an important role in regulating
melatonin diurnal synthesis. Indeed, it has been demonstrated that in
darkness, when the complex is formed, the amount of melatonin pro-
duced in the pineal gland can increase by 10 fold (Jones et al., 1995;
Klein et al., 2002).
Interestingly, the degree of AANAT phosphorylation correlates with
TRPV4 functionality. Application of a selective agonist of TRPV4 ex-
pressed in non-pigmented ciliary body epithelial cells results in a robust
increment of AANAT phosphorylation (Alkozi et al., 2017b). As a
consequence, phosphorylated AANAT is more active and more mela-
tonin is produced and released to the extracellular medium. The in-
tracellular chain of events in these cells involve the calmodulin-de-
pendent protein kinase II (CAMPKII) (Alkozi et al., 2017b). In fact, the
sequence of human AANAT (GenBank: AAH92430.1) includes con-
sensus site for CAMPKII action (Pearson and Kemp, 1991; Songyang
et al., 1996). This pathway in eye-derived cells is different from the
“canonical” pathway in the pineal gland that is dependent on elevation
of cAMP levels and PKA-dependent AANAT phosphorylation (Fig. 7)
(Schomerus and Korf, 2005).
On the one hand, the participation of the TRPV4 channel in reg-
ulating AANAT activity and melatonin production in ciliary processes
could explain the increase in melatonin levels found in the aqueous
humor of patients with elevated IOP. On the other hand, it is suspected
that other factors impact on this issue, namely melatonin found in the
aqueous humor can come from other ocular cells.
A novel discovery in the epithelial cells of crystalline lens, another
structure where melatonin is synthesized (Abe et al., 1999), is the
presence of functional melanopsin (Alkozi et al., 2017d). One of the
functions of this light-responding receptor is the control of melatonin
synthesis; its activation by the short wavelength component of the light
leads to melatonin suppression (Quera Salva et al., 2017). Melanopsin is
a photosensitive protein, that mechanistically sustains the discovery (in
the 1920s) of Clyde Keeler, who noticed that rodless and coneless mice
could still respond to light stimulus by pupil constriction (Keeler,
Fig. 5. Correlation between melatonin
concentration and IOP. Melatonin con-
centration in the aqueous humor of
control (normotensive) and glaucoma-
tous DBA mice. Melatonin was isolated
by HPLC and levels were compared in
animals (C57 and DBA) at 3 an 12
months of age (*p < 0.001; Wilcoxon
for paired samples). Panel B:
Relationship between melatonin con-
centration (ng/ml) in aqueous humor
of glaucomatous (DBA2/J) and non-
glaucomatous (C57) mice strains and
the IOP was statistically significant
(Pearson correlation analysis:
p < 0.001; r = 0.851). Modified from
(Alkozi et al., 2017a) with permission
(Wiley).
Fig. 6. Activation of TRPV4 expressed
in human ciliary body epithelial cells
induces the expression of AANAT and
melatonin synthesis. Panel A: Dose-re-
sponse data using different concentra-
tions of the TRPV4 agonist. Data are
the mean ± SEM (n = 5). Panel B:
Time-course of the effect of
GSK1016790A on melatonin synthesis.
Values represent the mean ± SEM
(n = 6; *p < 0.05, **p < 0.01,
***p < 0.001 versus time 0). Taken
from (Alkozi et al., 2017c: open ac-
cess).
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1928). This was the first evidence of a photoreceptor in the eye; several
years later Provencio and colleagues identified a small sub-class of
retinal ganglion cells expressing a photosensitive “receptor”, mela-
nopsin (Provencio et al., 2000). Light activation of this receptor leads to
cell depolarization whereas light leads to hyperpolarization in rods and
cones (Qiu et al., 2005). After light stimulation, melanopsin in retinal
ganglion cells triggers signalling via Gq/11, thus leading to the acti-
vation of phospholipase C (PLC), hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2) and subsequent increase in cytosolic Ca2+;
overall, light leads to depolarization of the plasma membrane of retinal
cells containing the receptor (Koyanagi and Terakita, 2008; Valdez
et al., 2009). When light activates melanopsin, signals are transmitted
from the retina through the retinohypothalamic tract to the su-
prachiasmatic nucleus (SCN) and to the cervical superior ganglion and
the pineal gland where melatonin synthesis is suppressed (Quera Salva
et al., 2017).
Recently, melanopsin presence in the cornea and the crystalline lens
was identified (Alkozi et al., 2017d; Delwig et al., 2018). Studies using
human crystalline epithelial cells showed that different light conditions
were able to produce changes in melatonin levels in the extracellular
medium, in fact, blue light activated melanopsin protein leading to
melatonin reduction in comparison to cells incubated under constant
darkness or red light. This action was mediated by phospholipase C
(PLC) as in the case of melanopsin activation in retinal ganglion cells.
These changes in melatonin levels also correlated with the activity of
AANAT (Alkozi et al., 2017d). Light ability to regulate in the lens both
melatonin levels and the activity of synthesizing enzymes is a relevant
factor to consider. Further studies are needed to relate these findings
with melatonin concentration in eye hypertension. Work using New
Zealand white rabbits revealed circumstantial evidence for such link.
Animals under 12/12 light/darkness cycles but only exposed to yellow
light had a decrease in IOP in comparison to control animals living
under dark/white light standard cycles. The results were concomitant
with an elevation of melatonin levels in the aqueous humor; moreover,
ocular hypotensive effect was blocked by the instillation of melatonin
receptor antagonists. Blockade by luzindole, a non-selective melatonin
receptor antagonist and by 4-P-PDOT, a MT2 selective antagonist,
confirmed that the effect was mediated by melatonin receptors (Lledo
et al., 2019). These findings are of significant relevance since an en-
vironmental factor, light, regulates melatonin content by directly acting
on the eye and, furthermore, on doing so it also regulates IOP (Pintor,
2018).
2.3.1. Melatonin and its analogues are efficacious ocular hypotensives
Is melatonin efficacious to reduce IOP in patients with glaucoma
that already have elevated levels of the indoleamine? (Martinez-Aguila
et al., 2016). As earlier mentioned, melatonin is an efficacious hypo-
tensive agent when applied to normotensive eyes. Patients undertaking
cataract surgery are given oral tablets of melatonin (10 mg; before the
surgery). In these patients with normotensive eyes (IOP: 17.9 mmHg)
melatonin significantly reduces IOP to 13.8 mmHg during cataract
surgery. This intervention is known to result in better surgical condi-
tions and outcomes (Ismail and Mowafi, 2009). On the other hand,
reduction in IOP may be achieved in glaucoma patients using agome-
latine, a melatonin analogue used as anti-depressant (Pescosolido et al.,
2015). Moreover, topical instillation of agomelatine in New Zealand
white rabbits resulted in a similar IOP reducing effect in both normo-
tensive and hypertensive conditions (Martinez-Aguila et al., 2013).
A significant number of melatonin analogues have shown hypo-
tensive efficacy: melatonin itself, N-acetyltryptamine, 6-chlor-
omelatonin, 2-iodomelatonin, 2-phenylmelatonin and 5-MCA-NAT.
While all were efficacious in New Zealand white rabbits, 5-MCA-NAT
was the most efficacious (42.5% IOP reduction). More interestingly, 5-
MCA-NAT displayed a sustained effect which lasted for more than
8 h, > 3 h more than that of other tested compounds (Pintor et al.,
2003). This effect of 5-MCA-NAT was thought to be mediated by the
putative MT3 melatonin receptor (Pintor et al., 2001). The promising
potential of 5-MCA-NAT in reducing IOP, was confirmed in a time-
course study that revealed that a single dose of the compound may
lower IOP for up to 96 h (Crooke et al., 2012). Carbonic anhydrases
affect aqueous humor secretion (Brechue and Maren, 1993), in fact,
their inhibitors are used to reduce IOP, either alone or in combination
with timolol, a β-blocker (Turk et al., 2015). Studies conducted to un-
derstand the mechanisms underlying the hypotensive effect of 5-MCA-
NAT and to check if the compound regulated the transcription of car-
bonic anhydrase genes did not serve to identify the molecular mode of
action. On the one hand, the combination of 5-MCA-NAT and a car-
bonic anhydrase inhibitor approved for therapy, dorzolamide, had
stronger hypotensive capacity, something that does not fit with a car-
bonic-anhydrase-mediated action. On the other hand, using the New
Zealand white rabbit as a model, 5-MCA-NAT significantly decreased
the expression of carbonic anhydrase 2 (CAII) and 12 (CAXII) in in vivo
Fig. 7. Scheme of events in the ciliary body trig-
gered upon TRPV4 channel activation. Upon agonist
activation of TRPV4 using GSK1016790A, a Ca2+
influx occurs and the ion binds to calmodulin (CM)
to indirectly activate adenylyl cyclase and protein
kinase A (PKA). This kinase will finally produce the
phosphorylation of cAMP response-element-binding
(pCREB) thus promoting the synthesis of the en-
zyme AANAT. On the other hand, CM binds to cal-
cium-CM dependent kinase II to phosphorylate
AANAT. This protein together with HIOMT will fi-
nally augment the production of melatonin in ciliary
body epithelial cells. It should be noted that TRPV4
channel can be stimulated by the abnormal eleva-
tion in the IOP often occurring in glaucoma.
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and in vitro assays (Crooke et al., 2012). Accordingly, 5-MCA-NAT
likely reduces IOP by a carbonic anhydrase-independent mechanism.
Interestingly, in vitro studies in non-pigmented ciliary body epi-
thelial cells revealed that melatonin and 5-MCA-NAT were able to
significantly down regulate the expression of the β2-adrenergic receptor
while causing α2A receptor up-regulation. These results are relevant
since adrenergic receptors are important players in regulating the
aqueous humor production in the ciliary processes (Greenfield et al.,
1997). Accordingly, when New Zealand white rabbits were primed with
melatonin or 5-MCA-NAT, and then daily treated with either timolol
(non-selective β-adrenergic receptor antagonist) or brimonidine (se-
lective α2A-adrenergic agonist), melatonin and 5-MCA-NAT potentiated
the hypotensive effect of the adrenoceptor-acting drugs (Crooke et al.,
2013). It is noteworthy to comment that combined therapy for the
control of glaucoma is a common method when monotherapy is no
longer effective (Sakanaka et al., 2008), therefore, melatonin used ei-
ther in combination with other agents or only as pre-treatment could be
effective to achieve stronger and long lasting hypotensive effect.
Moreover, the application of IIK7, a selective MT2 receptor agonist and
melatonin analogue, afforded a 38.5% IOP reduction. The effect was
severely diminished after chemical sympathectomy using reserpine or
6-hydroxydopamine (Alarma-Estrany et al., 2007). Taken together
these results suggest that IOP reduction by IIK7 or melatonin is medi-
ated mainly by MT2 receptors and that targeting the β-adrenoceptor
maximizes the effect.
Eye retinal pigment functionality in vertebrates is key to preserve a
correct activity of retinal neurons. Disfunction of epithelial ion trans-
port mechanisms can electroretinogram, which measures electrical ac-
tivity (Gallemore et al., 1997). The DBA/2J mice, which develops
glaucoma at 9 months of age, as shown by high IOP values and marked
alteration in the electroretinogram (Fig. 8), is instrumental as it is
considered a model of glaucoma that, furthermore, presents markedly
high IOP values at the onset of hypertension (Perez de Lara et al.,
2014). Experiments using this model proved that melatonin was able to
normalize IOP; melatonin had a hypotensive effect of 19.4% in control
mice, and 32.6% when applied to the eye of the glaucoma DBA/2J mice
model (Martinez-Aguila et al., 2016). Melatonin has been also tested in
the model of elevated intraocular pressure induced by the Trendelen-
burg position (Mizumoto et al., 2017), which consists of placing the
animal at 80° with the head in a lower position with respect to the rest
of the body. The position is maintained for 20 min and the pharmaco-
logical treatment is made 2 h after animal resting. This methodology
assayed using New Zealand rabbits proved that melatonin and agome-
latine were effective. Agomelatine applied to normotensive animals
reduced IOP by 21%, while in the hypertensive condition, the effect of
the compound was huge (69%) (Martinez-Aguila et al., 2013). In
summary, melatonin and analogues are even more effective hypoten-
sives when hypertensive glaucoma is established.
In view of the remarkable effect that 5-MCA-NAT was producing
over IOP, and to confirm the long lasting effect and safety of this
melatonin's analogue, glaucoma was induced in another animal model;
the non-human primate Macaca fascicularis in which trabecular mesh-
work is photocoagulated. 5-MCA-NAT application in this model
confirmed that the compound is capable of afford both significant and
long lasting IOP reduction. More importantly, the treatment was safe
with no signs of ocular side effects or systemic adverse reactions (Serle
et al., 2004).
2.3.2. Recent advances in melatonin-receptor-mediated mechanism leading
to IOP decrease
In vivo studies showed that melatonin receptor activation is the main
cause of IOP reduction (Pintor et al., 2003). MT1 and MT2 receptors
belong to the superfamily of G-protein-coupled receptors (GPCRs) that
is the largest class of cell surface receptors within the mammalian
proteome. Interestingly, about a 40% of all current prescription drugs
target GPCRs (Drews, 1996; Prinster et al., 2005). The current phar-
macology of melatonin receptors suggests that targeting the receptors
in individual fashion cannot explain why its activation leads to IOP
reduction, especially when there is both hypertension and increased
melatonin levels. Among the various alternative mechanisms, func-
tional units constituted by melatonin receptors in complex with other
proteins must be considered.
Usually described as receptors acting individually, more than 600
entities have been described that are constituted by (at least) two
GPCRs (Borroto-Escuela et al., 2014). Indirect evidence suggesting a
direct interaction between GPCR receptors (Krawietz et al., 1979;
Limbird et al., 1975) was followed by observations (in the early 80s),
showing that substance P could modulate the high-affinity serotonin
binding sites in spinal cord membrane preparations using biochemical
binding techniques (Agnati et al., 1980). Fuxe, Agnati and colleagues
emitted then the hypothesis of direct receptor-receptors interactions
that, around 20 years later, was proved. Identification of a heteromer
constituted by two receptors for the same endogenous opioid peptides
(Gomes et al., 2000) was followed by identification of the first het-
eromer constituted by GPCRs for two different neurotransmitter/neu-
romodulators (Gines et al., 2000). Ulterior development of ad hoc
techniques, for instance Bioluminescence Energy Resonance Transfer
(BRET) (Angers et al., 2000), has allowed advances in the discovery of
several GPCRs heterodimers, even heteromultimers, getting insight into
their physiological role. Occurrence of GPCR heteromers and differ-
ential expression in diseases (Bonaventura et al., 2014; Pinna et al.,
2014) has paved the way of a new area of research that opens a myriad
possibilities from both physiological and pharmacological points of
view. First of all, it should be highlighted that GPCR heteromers, by
definition, display properties that are new, i.e. not displayed by re-
ceptors when individually expressed (Ferre et al., 2009). In addition to
fundamentally changing our views on the quaternary structure and
activation mechanism, the concept of homo- and hetero-dimerization
may have a dramatic impact on drug development and screening
(Prinster et al., 2005). GPCR heteromerization appears as a good sub-
strate to explain previously unexpected pharmacological profiles and
signalling patterns. The challenge of translating findings in hetero-
logous systems to physiological environments has been solved by means
of two complementary approaches, namely by detection of the so-called
heteromer fingerprint (Franco et al., 2016) and by imaging receptor
clusters using the in situ proximity ligations assay (Agnati et al., 2003;
Borroto-Escuela et al., 2014; Soderberg et al., 2006).
There is now cumulative evidence showing that melatonin receptor
as other GPCR do form heteromers that are functionally relevant
(Prinster et al., 2005). It has been reported that MT1 and MT2 receptors
may form heteromers in a heterologous expression system (Ayoub et al.,
2002, 2004). By analogy with the A1-A2A receptor heteromer, those
heteromers could be melatonin concentration sensors. The A1-A2A re-
ceptor heteromer senses the extracellular concentration of adenosine to
signal via Gs or via Gi. Furthermore, the functionality of A1-A2A het-
eroreceptors is mediated by the long C-terminal domain of the A2A
(Navarro et al., 2016, 2018). Existing data do not support a similar role
for MT1-MT2 receptor complexes as the affinity for melatonin is similar
(Browning et al., 2000) and the C-terminal domains are similar and not
Fig. 8. Electroretinogram in control C57BL/6J (blue) and DBA/2J (red) mice.
Positive scotopic threshold response (pSTR) amplitude was significantly re-
duced in the DBA/2J glaucomatous at 9 months of age (p < 0.00001). Taken
from (Alkozi et al., 2019).
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particularly long (UNIPROT human sequences: P48039 and P49286).
Furthermore, data linking MT1-MT2 receptor heteromer to modulation
of photoreceptor function (Baba et al., 2013) or scotopic T electro-
retinogram (Piano et al., 2018) are not reliable due to the lack of ap-
propriate controls. There are few tools available to demonstrate het-
eromer involvement in a given process and all pass by disrupting the
heteromer in a very specific manner. Unfortunately, authors used KO
animals that do not serve for such purpose (Franco and Franco, 2014).
The reason is easy to convey, as a KO animal for, say the MT1 receptor,
will not display any MT1-containing heteromer. Accordingly, any loss of
function in the KO can be due to the lack of one, two or several of the
heteromers in which MT1 participate. In fact MT1 receptors may in-
teract with other GPCRs such as GPR50 (Levoye et al., 2006), whereas
the MT2 receptor may interact with serotonin 5-HT2C and with GPR61,
GPR62, and GPR135 receptors (Kamal et al., 2015; Oishi et al., 2018).
Although the cognate G protein coupled to melatonin receptors is
Gi, early studies dated back in the nineties showed that receptor acti-
vation could also lead to inositol phosphate production thus meaning
that Gq coupling was possible (Brydon et al., 1999). The promiscuity in
GPCR-G interactions may be an artifact resulting from differential ex-
pression of G proteins in different models and/or different experimental
setups but it also may derive from GPCR heteromerization. The latter, if
confirmed in natural cells, has enormous physiological relevance in
both healthy and diseased conditions. To our knowledge, the first re-
ported shift of coupled G proteins was reported by the laboratory of
Susan George, that showed that dopamine D1 receptors couple to Gs, D2
receptors couple to Gi and D1-D2 receptor heteromer couple to Gq
(Hasbi et al., 2009, 2010; Rashid et al., 2007). In the field of melatonin
receptors, Gq activation is possible within the MT2/5-HT2C heteromeric
context (Kamal et al., 2015). In summary, despite a given receptor has
its cognate G protein, different G proteins may be activated when the
receptor is forming part of a heteroreceptor functional unit. It is
tempting to speculate that melatonin may engage Gi, Gq or Gs de-
pending on the heteromer expressed in the target cell. In fact, apart
from the above-described examples of Gi and Gq coupling, Gs coupling
was reliably demonstrated by (Huete-Toral et al., 2015) in non-pig-
mented ciliary epithelial cells. What is important is the link between
melatonin-induced cAMP production and the regulation of chloride
channels as this mechanism may be involved in the eye pressure low-
ering capability of the natural indoleamine (Alkozi et al., 2019). The
mechanism involves MT1/MT2-receptor-containing heteromers, which
appear altered in the human glaucomatous eye. As earlier commented,
adrenoceptors are key in eye physiology. Remarkably, an adrenergic
agonist, phenylephrine, did not produce Ca2+ responses in cells ex-
pressing either α1A adrenergic-MT1 receptor heteromers or α1A adre-
nergic-MT2 receptor heteromers, despite the fact that Gq is the cognate
protein of this specific adrenoceptor. Such uncoupling seems beneficial,
i.e. the lack of adrenergic-induced calcium-mediated events is what is
happening in the healthy eye. On the other hand, these α1A receptor-
containing heteromeric complexes couple to Gs and, therefore, receptor
activation contributes, via cAMP and PKA activation, to keep IOP
within reference values (in the healthy eye). It turns out, that in the
ciliary body of the glaucomatous eye, both in animal models and in
samples from “real” cases (glaucoma patient eyes) expresses few func-
tional adrenergic-melatonin heteroreceptor units and the altered sig-
nalling mediated by individual receptors, especially by Gq-coupled α1A
adrenoceptors, negatively impacts on IOP due to significant increases in
cytosolic [Ca2+]. The concomitant increase in calcium ion and the
decrease in cAMP in ciliary body cells correlate with increased IOP
likely due to altered chloride channel activity both by hydrostatic
causes and by imbalance in the PKA-mediated regulation. These find-
ings have led to propose a combination therapy consisting of melatonin
and prazosin, an α1A adrenoceptor antagonist that, tested in animal
models, have provided spectacular results. Prazosin, not only enhanced
melatonin hypotensive action (to 9.0 ± 0.5 mmHg) but its effect lasted
more than 6 h, thus indicating a very appropriate therapeutic time
window (Alkozi et al., 2019). The summary of events taking into ac-
count these findings is displayed in Fig. 9. Adrenergic-melatonin het-
eroreceptor complexes are key in controlling IOP in the normotensive
eye; its disruption in glaucoma contributes to the disease but, im-
portantly, offer a new therapeutic avenue that has been successfully
tested in glaucoma models. Since prazosin is approved for human
therapy and melatonin is safe (even available for oral consumption
without being subjected to specific FDA regulations), a combined
melatonin-prazosin topical intervention (eye drops) could readily enter
into clinical trials to test efficacy in glaucoma.
3. Future development
Among the different sides to look at eye-melatonin relationships,
there are two we would like to highlight, namely the expression of
melatonin-related proteins in the different structures of the eye and the
Fig. 9. Signalling via melatonin receptors in ciliary
body cells of the normotensive and in the hy-
pertensive eye. In the normotensive eye melatonin
receptors form complexes with α1-adrenoceptors
and these functional units couple to Gs thus leading
to increase in cAMP levels, and PKA activity (left).
In the hypertensive eye the occurrence of in-
dividually expressed α1-adrenoceptors allows adre-
nergic agonists to increase cytosolic Ca2+ levels,
and the expression of individual melatonin re-
ceptors, which couple to Gi, leads melatonin to de-
crease cAMP levels and PKA activity (right).
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identification of the mode of action of melatonin in lowering the IOP in
both the healthy and the glaucomatous eye.
To get insight into the reason why melatonin application to the
hypertensive eye results in reduced tension despite the levels of the
indoleamine are already markedly elevated, it is needed to know
whether compartmentalization provides good answers. As it is not
possible to identify where melatonin is located, indirect evidence could
come from measuring the expression of the mRNAs of synthesizing
enzymes in the different ocular structures. In our opinion the use of a
technical development that has been recently improved and made ea-
sily available would provide the required information at the cell level.
The RNAscope®-based methodology allows measuring the level of
mRNA in tissue sections at the single-cell level (Wang et al., 2012).
Therefore, it is now possible to assess the expression of melatonin-
synthesizing enzymes simultaneously in all cell types and in all ocular
structures. This possibility of direct comparison in the same sample and
same conditions (for instance in samples taken at daylight or at night)
would accelerate discovery of melatonin actions in the different cells
and how they may vary due to circadian rhythms. In parallel, it would
be extremely relevant to use the same approach to measure the ex-
pression of proteins mediating the action of melatonin, including but
not restricted to MT1 and MT2 receptors.
As elsewhere described, the actions of cell surface receptors are
complex, specially in what concerns the link between early events and
distal actions affecting transcription regulation (Navarro et al., 2017).
Furthermore, melatonin has two canonical cell surface GPCRs (MT1 and
MT2) but other potential targets that might not be GPCRs. Melatonin is
indeed a pleiotropic molecule (Hardeland, 2009). The actions of mel-
atonin on gene transcription may be indirect although they were first
described as reflecting direct interaction with nuclear receptors. A re-
cent review shows the relevance of sirtuin involvement, which leads to
deacetylation of poly ADP ribose polymerase-γ coactivator-1α (PGC-
1α) and facilitation of retinoic acid receptor-related orphan receptor-α
binding to its response element; this mechanism may result from mel-
atonin receptor activation or be mediated by other players (Hardeland,
2018). In summary, the mode of action of melatonin may be hetero-
geneous with some effects mediated by cell surface receptors and some
effects mediated by other targets. Accordingly revisiting the huge
amount of melatonin-related data may provide some information on
GPCR-independent effects. In addition, it is worth considering some
possibilities for GPCRs that have not been explored in full for MT1 and
MT2 receptors. In fact, GPCRs may form heteromers and melatonin
receptor lack behind others such as adenosine or dopamine receptors
(Hasbi et al., 2009, 2010; Hinz et al., 2018; Rashid et al., 2007) in
looking for partners and differential signalling. Reliable data showing
coupling to G proteins other than Gi should not be neglected. Apart
from those above commented, there are quite a number of potential
interactions with receptors that are highly expressed in the eye; worth
testing potential interactions with other adrenoceptors, with dopamine
receptors and with melacortin receptors. The relevant finding would
not be the interaction per se but the possibility of differential G protein
coupling and differential signalling thus providing the mechanistic
basis of particular modes of action of melatonin depending on the cell
type and on the physiopathological condition.
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